Haemonetics (HAE) Liabilities and Shareholders Equity (2010 - 2026)

Haemonetics has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $2.4 billion in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 3.93% year-over-year to $2.4 billion in Q2 2026; TTM through Jun 2026 was $9.7 billion, a 2.76% decrease from a year earlier, with the FY2026 full-year figure at $2.4 billion, down 2.24% from the prior year.
• Liabilities and Shareholders Equity was $2.4 billion for Q2 2026 at Haemonetics, down from $2.4 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $2.5 billion in Q2 2024, with the low at $1.8 billion in Q3 2022.
• Average Liabilities and Shareholders Equity over 5 years is $2.2 billion, with a median of $2.2 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity jumped 38.94% in 2022, then slipped 3.93% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $1.9 billion in 2022, then rose by 17.16% to $2.2 billion in 2023, then grew by 15.04% to $2.5 billion in 2024, then slipped by 1.6% to $2.5 billion in 2025, then decreased by 5.04% to $2.4 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $2.4 billion (Q2 2026), $2.4 billion (Q1 2026), and $2.5 billion (Q4 2025), per Business Quant data.